Stereotactic body radiation therapy for the treatment of early-stage minimally invasive adenocarcinoma or adenocarcnioma in situ (formerly bronchioloalveolar carcinoma): a patterns of failure analysis

Radiation Oncology

Clifford G Robinson¹  Jeffrey D Bradley¹  Todd DeWees¹  Adam A Garsa¹  Kimberly M Creach¹  Jeffrey R Olsen¹  Andrew J Bierhals²  Shahed N Badiyan¹ 

[1] Department of Radiation Oncology, Mallinckrodt Institute of Radiology, Washington University in St. Louis, 4921 Parkview Place, Campus Box 8224, St. Louis, MO, 63110, USA;Department of Radiology, Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, USA

关键词: SABR;    BAC;    Minimally invasive adenocarcinoma;    Adenocarcinoma in situ;    Bronchioloalveolar carcinoma;    SBRT;   

Others  :  1154791
DOI  :  10.1186/1748-717X-8-4

 received in 2012-09-28, accepted in 2012-12-20,  发布年份 2013

【 摘 要 】

Introduction

Ongoing prospective trials exploring stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC) often exclude minimally invasive adenocarcinoma or adenocarcnioma in situ, formerly bronchioloalveolar carcinoma (BAC), due to concerns for accurate target delineation on CT. We performed a patterns of failure analysis to compare outcomes between BAC and other NSCLC subtypes.

Methods

One hundred twenty patients with early stage NSCLC were treated with SBRT from 2004–2009. Pathologic confirmation of NSCLC was obtained in 97 patients. Radiotherapy was delivered according to RTOG guidelines. The log-rank test was used to compare outcomes between BAC and other NSCLC.

Results

Median follow-up was 29 months. The median SBRT dose was 5400 cGy. Thirteen patients had radiographically diagnosed BAC and five patients had biopsy confirmed BAC, of which two had both. The three-year local control was 100% for biopsy-proven or radiographically diagnosed BAC (n = 18) and 86% for all other NSCLC subtypes (n = 102) (p = 0.13). Likewise, no significant difference was detected between BAC and other NSCLC for 3-year regional failure (12% vs. 20%, p = 0.45), progression-free survival (57.6% vs. 53.5%, p = 0.84) or overall survival (35% vs. 47%, p = 0.66). There was a trend towards lower three-year rates of freedom from distant failure in patients with any diagnosis of BAC compared to those without (26% vs. 38%, p = 0.053).

Conclusions

Compared to other NSCLC subtypes, BAC appears to have similar patterns of failure and survival after treatment with SBRT, however there may be an increased risk of distant metastases with BAC. RTOG guideline-based target delineation provides encouraging local control rates for patients with BAC.

【 授权许可】

   
2013 Badiyan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]NCCN: Clinical Practice Guidelines in Oncology version 2.2012. National Comprehensive Cancer Network; 2012. http://www.nccn.org
• [2]Fakiris AJ, McGarry RC, Yiannoutsos CT, et al.: Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009, 75:677-682.
• [3]Timmerman R, Paulus R, Galvin J, et al.: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA: j Am Med Assoc 2010, 303:1070-1076.
• [4]Shibamoto Y, Hashizume C, Baba F, et al.: Stereotactic body radiotherapy using a radiobiology-based regimen for stage I nonsmall cell lung cancer: A multicenter study. Cancer 2012, 118:2078-2084.
• [5]Andratschke N, Zimmermann F, Boehm E, et al.: Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: patterns of failure. Radiother oncol: j European Soc Therap Radiol Oncol 2011, 101:245-249.
• [6]Taremi M, Hope A, Dahele M, et al.: Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. Int J Radiat Oncol Biol Phys 2012, 82:967-973.
• [7]Bradley JD, El Naqa I, Drzymala RE, et al.: Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant. Int J Radiat Oncol Biol Phys 2010, 77:1146-1150.
• [8]Ricardi U, Filippi AR, Guarneri A, et al.: Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. Lung Cancer 2010, 68:72-77.
• [9]Baumann P, Nyman J, Hoyer M, et al.: Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J clin oncol: off j Am Soc Clin Oncol 2009, 27:3290-3296.
• [10]Travis WD, Brambilla E, Noguchi M, et al.: International association for the study of lung cancer/american thoracic society/european respiratory society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc 2011, 8:381-385.
• [11]Noguchi M, Morikawa A, Kawasaki M, et al.: Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995, 75:2844-2852.
• [12]Barsky SH, Cameron R, Osann KE, et al.: Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features. Cancer 1994, 73:1163-1170.
• [13]Read WL, Page NC, Tierney RM, et al.: The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database. Lung Cancer 2004, 45:137-142.
• [14]Gandara DR, Aberle D, Lau D, et al.: Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J thoracic oncol: off publ Int Assoc Study Lung Cancer 2006, 1:S20-S26.
• [15]Sabloff BS, Truong MT, Wistuba II, et al.: Bronchioalveolar cell carcinoma: radiologic appearance and dilemmas in the assessment of response. Clin lung cancer 2004, 6:108-112.
• [16]Kuriyama K, Seto M, Kasugai T, et al.: Ground-glass opacity on thin-section CT: value in differentiating subtypes of adenocarcinoma of the lung. AJR Am j roentgenol 1999, 173:465-469.
• [17]Raz DJ, Kim JY, Jablons DM: Diagnosis and treatment of bronchioloalveolar carcinoma. Current opinion pulmonary med 2007, 13:290-296.
• [18]Yap CS, Schiepers C, Fishbein MC, et al.: FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma? Eur J Nucl Med Mol Imaging 2002, 29:1166-1173.
• [19]Aquino SL, Halpern EF, Kuester LB, et al.: FDG-PET and CT features of non-small cell lung cancer based on tumor type. Int j mol med 2007, 19:495-499.
• [20]Sun JS, Park KJ, Sheen SS, et al.: Clinical usefulness of the fluorodeoxyglucose (FDG)-PET maximal standardized uptake value (SUV) in combination with CT features for the differentiation of adenocarcinoma with a bronchioloalveolar carcinoma from other subtypes of non-small cell lung cancers. Lung Cancer 2009, 66:205-210.
• [21]Raz DJ, He B, Rosell R, et al.: Bronchioloalveolar carcinoma: a review. Clin lung cancer 2006, 7:313-322.
• [22]Kim BT, Kim Y, Lee KS, et al.: Localized form of bronchioloalveolar carcinoma: FDG PET findings. AJR Am j roentgenol 1998, 170:935-939.
• [23]NCT00551369: Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery. Radiation Therapy Oncology Group; 2012. http://www.rtog.org
• [24]NCT00960999: Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer. Radiation Therapy Oncology Group; 2012. http://www.rtog.org
• [25]Patsios D, Roberts HC, Paul NS, et al.: Pictorial review of the many faces of bronchioloalveolar cell carcinoma. Br J Radiol 2007, 80:1015-1023.
• [26]Lee HJ, Lee CH, Jeong YJ, et al.: IASLC/ATS/ERS international multidisciplinary classification of lung adenocarcinoma: novel concepts and radiologic implications. J thoracic imaging 2012, 27:340-353.
• [27]Phase I/II Study of Stereotactic Body Radiotherapy in Medically Inoperable Patients With Centrally Located Stage I Non-Small Cell Lung CancerAvailable at http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid = 613524&version = HealthProfessional&protocolsearchid = 6830592 webcite. Accessed May 24, 2012
• [28]Whitson BA, Groth SS, Andrade RS, et al.: Invasive adenocarcinoma with bronchoalveolar features: a population-based evaluation of the extent of resection in bronchoalveolar cell carcinoma. J Thorac Cardiovasc Surg 2012, 143:591-600. e591
• [29]Koike T, Togashi K, Shirato T, et al.: Limited resection for noninvasive bronchioloalveolar carcinoma diagnosed by intraoperative pathologic examination. Ann Thorac Surg 2009, 88:1106-1111.
• [30]Sagawa M, Higashi K, Usuda K, et al.: Curative wedge resection for non-invasive bronchioloalveolar carcinoma. Tohoku J Exp Med 2009, 217:133-137.
• [31]Yamato Y, Tsuchida M, Watanabe T, et al.: Early results of a prospective study of limited resection for bronchioloalveolar adenocarcinoma of the lung. Ann Thorac Surg 2001, 71:971-974.
• [32]Liu YY, Chen YM, Huang MH, et al.: Prognosis and recurrent patterns in bronchioloalveolar carcinoma. Chest 2000, 118:940-947.
• [33]Johnson BE: Second lung cancers in patients after treatment for an initial lung cancer. J Nat Cancer Institute 1998, 90:1335-1345.
• [34]Ginsberg RJ, Rubinstein LV, Lung Cancer Study Group: Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer. Ann Thorac Surg 1995, 60:615-622. discussion 622–613